Riskpilot← Back to searchSign inGet full accessNORDLYSAPOTEKET AS
ASActiveOrg 984475330Markedsgata 21-25, 9510 AltaRetail sale of pharmaceutical products · NACE 4773Est. 20020 employees
Revenue 2021
NOK 43,5M
+4% vs 2020
EBITDA margin
11.0%
+10% vs 2020
Equity ratio
8.5%
Financial strength
Net profit 2021
NOK 3,8M
+10% vs 2020
| Revenue | NOK 43,5M | +4% |
| EBITDA | NOK 4,8M | +10% |
| Net profit | NOK 3,8M | +10% |
| Total assets | NOK 19,3M | +25% |
| Equity | NOK 1,6M | +19% |
| Employees | 0 | — |
Legal name
NORDLYSAPOTEKET AS
Org number
984475330
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
2. mai 2002
Share capital
NOK 10 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-01-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Apotekdrift, handel og det som naturlig hører inn under dette.
Address
Markedsgata 21-25, 9510 Alta
Phone
+4778446820
Email
apotek1.nordlys@apotek1.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 35 640 | 38 237 | 39 990 | 41 947 | 43 506 |
| Staff expenses | −5 497 | −5 400 | −5 415 | −5 990 | −5 751 |
| EBITDA | 3 109 | 3 576 | 3 945 | 4 355 | 4 804 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 3 109 | 3 576 | 3 945 | 4 355 | 4 804 |
| Net financials | 8 | 10 | 19 | 46 | 15 |
| Profit before tax | 3 117 | 3 586 | 3 964 | 4 401 | 4 819 |
| Tax | 750 | 827 | 874 | 970 | 1 061 |
| Net profit | 2 368 | 2 758 | 3 091 | 3 431 | 3 757 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 12 020 | 13 001 | 14 595 | 15 509 | 19 324 |
| Equity | 1 002 | 1 208 | 1 342 | 1 380 | 1 637 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 11 018 | 11 793 | 13 253 | 14 129 | 17 686 |
| Total debt | 11 018 | 11 793 | 13 253 | 14 129 | 17 686 |
EBITDA margin
11.0%
This company
15.8%
Market median
-30% vs market
20172021
Equity ratio
8.5%
This company
38.2%
Market median
-78% vs market
20172021
Return on equity
229.5%
This company
18.4%
Market median
+1147% vs market
20172021
Net profit margin
8.6%
This company
8.1%
Market median
+6% vs market
20172021
Asset turnover
2.25×
This company
1.12×
Market median
+101% vs market
20172021
Debt / equity
10.80×
This company
0.62×
Market median
-1642% vs market
20172021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-02-01 – 2021-01-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2019-02-01 – 2020-01-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2018-02-01 – 2019-01-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2017-02-01 – 2018-01-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2016-02-01 – 2017-01-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AD Chief Executive Officer | Chief Executive Officer | 2006 |
IJ Deputy Member | Deputy Member | 2005 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2005 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDLYSAPOTEKET AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Dåvøy | Chief Executive Officer | 0 companies |
| Inger Johanne Kristensen | Deputy Member | 0 companies |
| Hege Hillestad | Chairman | 0 companies |